PMID- 15778372
OWN - NLM
STAT- MEDLINE
DCOM- 20050607
LR  - 20201226
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 174
IP  - 7
DP  - 2005 Apr 1
TI  - Tumoricidal potential of native blood dendritic cells: direct tumor cell killing 
      and activation of NK cell-mediated cytotoxicity.
PG  - 4127-34
AB  - Dendritic cells (DCs) are characterized by their unique capacity for primary T 
      cell activation, providing the opportunity for DC-based cancer vaccination 
      protocols. Novel findings reveal that besides their role as potent inducers of 
      tumor-specific T cells, human DCs display additional antitumor effects. Most of 
      these data were obtained with monocyte-derived DCs, whereas studies investigating 
      native blood DCs are limited. In the present study, we analyze the tumoricidal 
      capacity of M-DC8(+) DCs, which represent a major subpopulation of human blood 
      DCs. We demonstrate that IFN-gamma-stimulated M-DC8(+) DCs lyse different tumor 
      cell lines but not normal cells. In addition, we show that tumor cells markedly 
      enhance the production of TNF-alpha by M-DC8(+) DCs via cell-to-cell contact and 
      that this molecule essentially contributes to the killing activity of M-DC8(+) 
      DCs. Furthermore, we illustrate the ability of M-DC8(+) DCs to promote 
      proliferation, IFN-gamma production, and tumor-directed cytotoxicity of NK cells. 
      The M-DC8(+) DC-mediated enhancement of the tumoricidal potential of NK cells is 
      mainly dependent on cell-to-cell contact. These results reveal that, in addition 
      to their crucial role in activating tumor-specific T cells, blood DCs exhibit 
      direct tumor cell killing and enhance the tumoricidal activity of NK cells. These 
      findings point to the pivotal role of DCs in triggering innate and adaptive 
      immune responses against tumors.
FAU - Schmitz, Marc
AU  - Schmitz M
AD  - Institute of Immunology, Medical Faculty, Technical University of Dresden, 
      Dresden, Germany. mschmitz@rcs.urz.tu-dresden.de <mschmitz@rcs.urz.tu-dresden.de>
FAU - Zhao, Senming
AU  - Zhao S
FAU - Deuse, Yvonne
AU  - Deuse Y
FAU - Schakel, Knut
AU  - Schakel K
FAU - Wehner, Rebekka
AU  - Wehner R
FAU - Wohner, Hanka
AU  - Wohner H
FAU - Holig, Kristina
AU  - Holig K
FAU - Wienforth, Florian
AU  - Wienforth F
FAU - Kiessling, Andrea
AU  - Kiessling A
FAU - Bornhauser, Martin
AU  - Bornhauser M
FAU - Temme, Achim
AU  - Temme A
FAU - Rieger, Michael A
AU  - Rieger MA
FAU - Weigle, Bernd
AU  - Weigle B
FAU - Bachmann, Michael
AU  - Bachmann M
FAU - Rieber, E Peter
AU  - Rieber EP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (CD8 Antigens)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Blood Cells
MH  - CD8 Antigens
MH  - Cell Communication
MH  - Cell Line, Tumor
MH  - *Cytotoxicity, Immunologic
MH  - Dendritic Cells/cytology/*immunology
MH  - Humans
MH  - Immunity
MH  - Killer Cells, Natural/*immunology
MH  - Lymphocyte Activation/immunology
MH  - Neoplasms/immunology/*pathology
MH  - Tumor Necrosis Factor-alpha/biosynthesis/physiology
EDAT- 2005/03/22 09:00
MHDA- 2005/06/09 09:00
CRDT- 2005/03/22 09:00
PHST- 2005/03/22 09:00 [pubmed]
PHST- 2005/06/09 09:00 [medline]
PHST- 2005/03/22 09:00 [entrez]
AID - 174/7/4127 [pii]
AID - 10.4049/jimmunol.174.7.4127 [doi]
PST - ppublish
SO  - J Immunol. 2005 Apr 1;174(7):4127-34. doi: 10.4049/jimmunol.174.7.4127.